Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

While several molecular markers that are used to evaluate the development and prognosis of bladder cancer have been studied, the limited value of these established markers has created the need for ...

Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival ...

to treat a subset of bladder cancer patients. The drug has been approved as an oral monotherapy for adults with unresectable ...

In addition, the proportion of muscle-invasive bladder cancer was limited and ... value in locally advanced invasive or metastatic urothelial cancer.

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing innovative treatments for urothelial and specialty cancers ... treatment for non-muscle invasive bladder cancer.

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on TYRA stock, giving a Buy rating on October 29. Tyler Van Buren has ...

November 4, 2024 Efficacy and Safety of Sacituzumab Govitecan in Cisplatin-Ineligible Patients with Metastatic Urothelial Cancer After Immunotherapy - Expert Commentary November 1, 2024 ...